Does a personal or family history of malignancy preclude the use of immunomodulators and biologics in IBD

Inflammatory Bowel Diseases

Volumn 21, Issue 2, 2015, Pages 428-435

  Kalman, Richard S ^a   Hartshorn, Kevan ^a   Farraye, Francis A ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biologics; Inflammatory bowel disease; Lymphoma; Malignancy; Methotrexate; Skin cancer; Thiopurines

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN; HYDROXYCHLOROQUINE; IMMUNOMODULATING AGENT; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; SALAZOSULFAPYRIDINE; VEDOLIZUMAB; BIOLOGICAL PRODUCT; IMMUNOLOGIC FACTOR;

BREAST CANCER; CANCER RISK; COLORECTAL CANCER; CROHN DISEASE; FAMILY HISTORY; FOLLOW UP; HEPATOSPLENIC T CELL LYMPHOMA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; KIDNEY CARCINOMA; LYMPHOMA; MEDICAL HISTORY; MELANOMA; PRIORITY JOURNAL; REVIEW; SKIN CANCER; T CELL LYMPHOMA; ULCERATIVE COLITIS; URINARY TRACT CANCER; UTERINE CERVIX CANCER; CHEMICALLY INDUCED; COMPLICATION; GENETIC PREDISPOSITION; GENETICS; INFLAMMATORY BOWEL DISEASES; NEOPLASM; PERSONALIZED MEDICINE;

BIOLOGICAL PRODUCTS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOLOGIC FACTORS; INDIVIDUALIZED MEDICINE; INFLAMMATORY BOWEL DISEASES; NEOPLASMS;

EID: 84927724692     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000211     Document Type: Review

References (82)

1. Hudesman D, Lichtiger S, Sands B. Risk of extraintestinal solid cancer with anti-TNF therapy in adults with inflammatory bowel disease: review of the literature. Inflamm Bowel Dis. 2013;19:644-649.
2. Kappelman MD, Farkas DK, Long MD, et al. Risk of cancer in patients with inflammatory bowel disease: A nationwide population-based cohort study with 30 years of follow up evaluation. Clin Gastroenterol Hepatol. 2014;12:265-273.
3. Shaukat A, Virnig DJ, Howard D. Crohns disease and small bowel adenocarcinoma: A population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2011;20:1120-1123.
4. Munkholm P. Review article: The incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18 (suppl 2):1-5.
5. Dyson JK, Rutter MD. Colorectal cancer in inflammatory bowel disease: what is the real magnitude of risk?. World J Gastroenterol. 2012;18: 3839-3848.
6. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut. 2001;48:526-535.
7. Lutgens W, Van Oijen MG, Van der Heijden GJ, et al. Declining risk of colorectal cancer in inflammatory bowel disease: An updated metaanalysis of population-based cohort studies. Inflamm Bowel Dis. 2013; 19:789-799.
8. Söderlund S, Brandt L, Lapidus A, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology. 2009;136:1561-1567; quiz 1818-1819.
9. Ekbom A, Helmick C, Zack M, et al. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet. 1990;336:357-359.
10. Singh S, Talwalkar JA. Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol. 2013;11:898-907.
11. Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology. 2011;54:1842-1852.
12. Burak K, Angulo P, Pasha TM, et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol. 2004;99:523-526.
13. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692-701.
14. Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001;121:1080-1087.
15. Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut. 2005;54:617-622.
16. Vos AC, Bakkal N, Minnee RC, et al. Risk of malignant lymphoma in patients with inflammatory bowel diseases: A Dutch nationwide study. Inflamm Bowel Dis. 2011;17:1837-1845.
17. Colombrel JF, Sandborn W, Reinisch W, et al. Infliximab, azathioprine or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
18. Ngueyn T, Vacek PM, O'Neil P, et al. Mutagenicity and potential carcinogenesis of thiopurine treatment in patients with inflammatory bowel disease. Cancer Res. 2009;69:7004-7012.
19. Karran P. Thiopurines, DNA damage, DNA repair and therapy-related cancer. Br Med Bull. 2006;79-80:153-170.
20. Pasternak B, Svanstrom H, Schmiegelow K, et al. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol. 2013; 177:1296-1305.
21. Kauffman HM, Cherikh WS, McBride MA, et al. Post-transplant de novo malignancies in renal transplant recipients: The past and present. Transpl Int. 2006;19:607-620.
22. Opelz G, Dohler B. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant. 2004;4:222-230.
23. Marcen R, Pascual J, Tato AM, et al. Influence of immunosuppression on the prevalence of cancer after kidney transplantation. Transplant Proc. 2003;35:1714-1716.
24. Beaugerie L. Use of immunosuppressants and biologics in patients with previous cancer. Dig Dis. 2013;31:254-259.
25. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005:54:1121-1125.
26. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: A prospective observation cohort study. Lancet. 2009;364:1617-1625.
27. Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: A UK population-based case-control study. Am J Gastroenterol. 2010;105:1604-1609.
28. O'Donovan P, Perrett CM, Zhang X, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science. 2005;309:1871-1874.
29. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011:141:1621-1628 e1-5.
30. Setshedi M, Epstein D, Winter T, et al. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of nonmelanoma skin cancer in an at-risk population: A cohort study. J Gastroenterol Hepatol. 2012;27:385-389.
31. Ariyaratnam J, Subramanian V. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: A meta-analysis. Am J Gastroenterol. 2014;109:163-169.
32. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;2003:1681-1691.
33. van den Reek J, van Lümig P, Janssen M, et al. Increased incidence of squamous cell carcinoma of the skin after long term treatment with azathioprine in patients with auto-immune inflammatory rheumatic diseases. J Eur Acad Dermatol Venereol. 2014;28:27-33.
34. Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:390-399.
35. Smith MA, Irving PM, Marinaki AM, et al. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther. 2010;32:119-130.
36. Kamel OW, Van De Rijn M, Weiss LM, et al. Brief report: reversible lymphomas associated with Epstein Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med. 1993;328:1317-1321.
37. Hannuksela-Svhan A, Pukkala E, Laara E, et al. Psoriasis, its treatment, and cancer in a cohort of Finish patients. J Invest Dermatol. 2000;114:587-590.
38. Mariette X, Casals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: A 3 year prospective study in France. Blood. 2002;99:3909-3915.
39. Buchbinder R, Barber M, Heuzenroeder L, et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 2008;59:794-799.
40. Salliot C, van der-Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic literature research. Ann Rheum Dis. 2009;68:1100-1104.
41. Farrell RJ, Ang Y, Kileen P, et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut. 2000;47:514-519.
42. Krathen MS, Gottlieb AB, Mease PJ. Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis. J Rheumatol. 2010;37:2205-2215.
43. Singh H, Nugent Z, Demers AA, et al. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology. 2011;141:1612-1620.
44. Beaugerie L. Inflammatory bowel disease therapies and cancer risk: where are we and where are we going? Gut. 2012;61:476-483.
45. Mariette X, MatucciM, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: A systematic review and meta-analysis. Ann Rheum Dis. 2011;70:1895-1904.
46. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-2285.
47. Bickston SJ, Lichtenstein GR, Arseneau KO, et al. The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology. 1999;177:1433-1437.
48. Alcaín G, Andrade RJ, Queipo de Llano MP, et al. Acute leukemia after infliximab therapy. Am J Gastroenterol. 2003;98:2577.
49. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: Twenty six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002:46;3151-3158.
50. Remicade: Full Prescribing Information. Available at: http://www.remicade.com/shared/product/remicade/prescribing-information.pdf. Accessed September 10, 2014.
51. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: A meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874-881.
52. Osterman M, Sandborn WJ, Colombel J, et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology. 2014;146:941-946.
53. Deepak P, Sifuentes H, Sherid M, et al. T cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013;108:99-105.
54. Lichtenstein GR, Feagan BG, Cohen RC, et al. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT registry. Am J Gastroenterol. 2014;109:212-223.
55. Andersen NN, Pasternak N, Basit S, et al. Association between tumor necrosis factor-alpha antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014;311:2406-2413.
56. Williams CJM, Peyrin-Biroulet L, Ford AC. Systematic review with metaanalysis: malignancies with anti-tumor necrosis factor alpha therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:447-458.
57. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: The Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
58. Herrinton LJ, Liu L, Weng X, et al. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011;106:2146-2153.
59. Subramanian K, D'Rozario J, Pavli P. Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: A review. J Gastroenterol Hepatol. 2013;28:24-30.
60. Subramanian K, Yeng D, Grimpen F, et al. Hepatosplenic T-cell lymphoma, immunosuppressive agents and biological: what are the risks?. Intern Med J. 2014;44:287-290.
61. Parakkal D, Sifuentes H, Semer R, et al. Hepatosplenic T-cell lymphoma in patients receiving TNF-a inhibitor therapy: expanding the groups at risk. Eur J Gastroenterol Heptaol. 2011;23:1150-1156.
62. Abbvie. Humira: Full Prescribing Information. Available at: http://www.rxabbvie.com/pdf/humira.pdf. Accessed September 10, 2014.
63. De Vries HS, van Oijen GH, de Jong DJ. Serious events with infliximab in patients with inflammatory bowel disease: A 9 year cohort study in the Netherlands. Drug Saf. 2008;31:1135-1144.
64. Zabana Y, Domenech E, Manosa M, et al. Infliximab safety profile and long term applicability in inflammatory bowel disease: A 9 year experience in clinical practice. Aliment Pharmacol Ther. 2010;31:553-560.
65. Planas R, Martin R, Sospedra M. Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life. Patient Relat Outcome Meas. 2014;5:25-33.
66. Bergamaschi R, Montomoli C. Melanoma in multiple sclerosis treatedwith natalizumab: causal association or coincidence? Mult Scer. 2009;15: 1532-1533.
67. Mullen JT, Vartanian TK, Atkins MB. Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med. 2008; 358:647-648.
68. Ismail A, Kemp J, Sharrack B. Melanoma complicating treatment with natalizumab (tysabri) for multiple sclerosis. J Neurol. 2009;256:1771-1772.
69. Laroni A, Bedognetti M, Uccelli A, et al. Association of melanoma and natalizumab therapy in the Italian MS population: A second case report. Neurol Sci. 2011;32:181-182.
70. Schweikert A, Kremer M, Ringel F, et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol. 2009;66: 403-406.
71. Schowinsky J, Corboy J, Vollmer T, et al. Natalizumab-associated complication? First case of peripheral T cell lymphoma. Acta Neuropathol. 2012;123:751-752.
72. Sanborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease: The ENACT-1 and ENACT-2 trials. N Eng J Med. 2005;353:1912-1925.
73. Takeda Pharmaceuticals U.S.A., Inc. Vedolizumab: Advisory committee briefing document. Available at: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/gastrointestinaldrugsadvisorycommittee/ucm377621.pdf. Accessed September 10, 2014.
74. Bernheim O, Colombel JF, Ullman TA, et al. The management of immunosuppression in patients with inflammatory bowel disease and cancer. Gut. 2013;62:1523-1528.
75. Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation. 1993;55:742.
76. Strangfeld A, Hierse F, Rau R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther. 2010;12:R5.
77. Dixon WG, Watson KD, Lunt M, et al. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res. 2010;62:755-763.
78. Swoger JM, Regueiro M. Stopping, continuing, or restarting immunomodulators and biologics when an infection or malignancy develops. Inflamm Bowel Dis. 2014;20:926-935.
79. Beaugerie L, Carrat F, Colobmel JF, et al. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut. 2014;63:1416-1423.
80. Lichtenstein GR, Hanauer SB, Sandborn WJ, et al. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104:465-483.
81. Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization Practice Guidelines for diagnosis and management of IBD in 2010. Inflamm Bowel Dis. 2010;16:112-124.
82. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis. 2010;4:28-62.